1-6 of 6
R. Willemze, MD
Close
Sort by
Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) in the Management of Advanced Waldenstrom’s Macroglobulinemia (WM).

Charalampia Kyriakou, MD, C. Canals, MD, A. Sureda, MD, G. Taghipour, J. Cornelissen, MD, R. Willemze, MD, G. Socie, MD, H. Greinix, MD, J. Kienast, MD, R. Hamladji, MD, M. Kazmi, MD, P. Jacobs, MD, N. Schmitz, MD
Journal: Blood
Blood (2007) 110 (11): 619.
https://doi.org/10.1182/blood.V110.11.619.619
Published: 2007
Journal Articles

First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions.

C.J.M. Halkes, MD, M.H. Vermeer, MD, E.M. Noordijk, MD, R. Willemze, MD, Roelof Willemze, MD
Journal: Blood
Blood (2006) 108 (11): 4669.
https://doi.org/10.1182/blood.V108.11.4669.4669
Published: 2006
Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

T.M. De Witte, MD, A. Hagemeijer, MD, S. Suciu, PhD, A. Belhabri, MD, M. Delforge, MD, C. Aul, MD, M. Aivado, MD, D. Selleslag, MD, H. Schouten, MD, A. Ferrant, MD, H. Biersack, MD, S. Amadori, MD, P. Muus, MD, U. Jehn, MD, F. Beeldens, J. Jansen, PhD, E. Hellstrom-Lindberg, MD, T. Kovacsovics, MD, U. Hess, MD, P. Wijermans, MD, G. Ossenkoppele, MD, A. Gratwohl, MD, J.-P. Marie, MD, R. Willemze, MD
Journal: Blood
Blood (2005) 106 (11): 794.
https://doi.org/10.1182/blood.V106.11.794.794
Published: 2005
Journal Articles

Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.

J.F. de Vries, MSc, P.A. von dem Borne, MD, PhD, M.H.M. Heemskerk, PhD, R. Willemze, MD, PhD, J.H.F. Falkenburg, MD, PhD, R.M.Y. Barge, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 1267.
https://doi.org/10.1182/blood.V104.11.1267.1267
Published: 2004
Journal Articles

A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.

M. Oosterveld, MD, S. Suciu, M.Sc, P. Muus, MD, M. Delforge, MD, A. Belhabri, MD, C. Aul, MD, D. Selleslag, MD, A. Ferrant, MD, J.-P. Marie, MD, S. Amadori, MD, U. Jehn, MD, U. Hess, MD, R. Willemze, MD, E. Hellstrom-Lindberg, MD, M. Vignetti, MD, B. Labar, MD, F. Mandelli, MD, T. De Witte, MD
Journal: Blood
Blood (2004) 104 (11): 2020.
https://doi.org/10.1182/blood.V104.11.2020.2020
Published: 2004
Journal Articles

Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).

M. Hoogendoorn, MD, J. Olde Wolbers, W. M. Smit, MD PhD, I. Jedema, PhD, M. R. Schaafsma, MD PhD, R. M.Y. Barge, MD PhD, R. Willemze, MD PhD, J. H.F. Falkenburg, MD PhD
Journal: Blood
Blood (2004) 104 (11): 2118.
https://doi.org/10.1182/blood.V104.11.2118.2118
Published: 2004